CG Oncology, Inc. · NASDAQ:CGON

CG Oncology — Investor Presentation (June 2024)

28 slides from CG Oncology's investor presentation, June 2024

  1. Slide 1: Attacking Bladder Cancer for a Better Tomorrow

    Attacking Bladder Cancer for a Better Tomorrow | 1

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and

  3. Slide 3: Investment Summary

    Investment Summary ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪

  4. Slide 4: Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC

    Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC Addressing a Multi-Billion Dollar Market Opportunity COMPOUND/INDICATION PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES BOND-003 Cohort C BCG-Unresponsive, High-Risk NMIBC (BOND-003) pivotal data in 2H’24 CORE-001 24-month BCG-Unrespons

  5. Slide 5: Executive Leadership Team

    Executive Leadership Team | 5

  6. Slide 6: Attacking Bladder Cancer for a Better Tomorrow

    Attacking Bladder Cancer for a Better Tomorrow

  7. Slide 7: Bladder Cancer is a Significant Unmet Medical Need

    Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption | 7

  8. Slide 8: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer

    NMIBC Represents a Multi-Billion insice othe Bladder wall Outside of the bladder wall bladder wall Dollar Market Opportunity in i Bladder Cancer Nonttusdeinmnive fl cis fl Bladder Cancer NMIBC Carcinoma in Situ (CIS) Non-Invasive Papillary Carcinoma Ta Tumor Invades Connective Tissue ~75% of Newly D

  9. Slide 9: Current NMIBC treatment paradigm

    (1) Symptom Ongoing Treatment Require surveillance and/or Patient presents to primary care treatment every 3 to 6 months and/or urologist with symptoms for 2 to 5 years (hematuria, urinary frequency) Testing Work-up may include cystoscopy, urine cytology, + Low-Risk and imaging (CT scan, MRI) Periop

  10. Slide 10: FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval

    FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval Single-arm trials with complete response rate as primary endpoint in the context of duration of response may be appropriate for a full approval. BCG-unresponsive disease defined as either: • Persistent o

  11. Slide 11: 1b 1a Creto

    1 2 1a 1b T-Cell Creto Tumor Progeny Antigens GM-CSF Cancer Cell

  12. Slide 12: Cretostimogene Selectively Targets Rb-E2F Pathway Defective Cancers

    Cretostimogene Selectively Targets Rb-E2F Pathway Defective Cancers Cretostimogene grenadenorepvec Cretostimogene grenadenorepvec in Normal Cells in Tumor Cells o o | 12

  13. Slide 13: Cretostimogene is Intravesically Administered into the Bladder

    Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly GAG Layer Tumor Standard Catheter Cretostimogene β | 13

  14. Slide 14: Ease of Delivery and Administration for Patients, Physicians, and Practice Providers

    Ease of Delivery and Administration for Patients, Physicians, and Practice Providers

  15. Slide 15: Our Goal is to Establish Cretostimogene as Backbone Therapy for NMIBC

    Our Goal is to Establish Cretostimogene as Backbone Therapy for High-Risk and Intermediate-Risk NMIBC Patients

  16. Slide 16: Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC (NCT04452591)

    Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC (NCT04452591) ▪ ▪ ▪ o o o ▪ o o o ▪ ▪ ▪ ▪ o o o

  17. Slide 17: Patient Demographics & Baseline Characteristics

    Patient Demographics & Baseline Characteristics ▪ Gender o o Age (Years) o ▪ Age (Categories) o BCG History: Number of Prior Instillations High-Risk NMIBC T-Stage at Study Entry

  18. Slide 18: Cretostimogene Monotherapy Results in Cohort C: Largest Dataset in BCG-Unresponsive, High-Risk NMIBC

    Cretostimogene Monotherapy Results in Cohort C: Largest Dataset in BCG-Unresponsive, High-Risk NMIBC ▪ ▪ ▪

  19. Slide 19: AUA 2024: Updated Results from BOND-003 Cohort C

    AUA 2024: Updated Results from BOND-003 Cohort C Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC ▪ ▪ ▪

  20. Slide 20: Cretostimogene Has Been Generally Well-Tolerated

    Cretostimogene Has Been Generally Well-Tolerated ▪ ▪ ▪ ▪ ▪

  21. Slide 21: Phase 2 Cretostimogene + Pembrolizumab for BCG-Unresponsive, High-Risk NMIBC CIS (NCT04387461)

    Phase 2 Cretostimogene + Pembrolizumab for BCG-Unresponsive, High-Risk NMIBC CIS (NCT04387461) CR at 12-months ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 3 All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR.

  22. Slide 22: Cretostimogene Combo with Pembrolizumab: Potential Class-Leading Response

    Cretostimogene Combo with Pembrolizumab: Potential Class-Leading Response ▪ ▪ ▪ ▪ o

  23. Slide 23: ASCO 2024: Updated Long-Term Durability Data

    ASCO 2024: Updated Long-Term Durability Data Cretostimogene + Pembrolizumab Combo for BCG-Unresponsive, High-Risk NMIBC

  24. Slide 24: Favorable Safety Profile with No Overlapping or Synergistic Toxicity in Combination

    Favorable Safety Profile with No Overlapping or Synergistic Toxicity in Combination of Cretostimogene and Pembrolizumab ▪ ▪ ▪ ▪ ▪

  25. Slide 25: Pioneering Class-Leading Oncolytic Immunotherapy with Differentiated Clinical Profile

    Pioneering Class-Leading Oncolytic Immunotherapy with Differentiated Clinical Profile Against Approved and Investigational NMIBC Agents1 Trial BOND-003 CORE-001 QUILT 3.032 NCT02773849 KEYNOTE-057 SunRISe-1 LEGEND Intervention Mechanism RoA Stage Sample Size CR at Any Time CR at 12 Mo CR at 24 Mo Do

  26. Slide 26: Phase 3 Adjuvant Cretostimogene Following TURBT Versus Surveillance for Intermediate-Risk NMIBC

    Phase 3 Adjuvant Cretostimogene Following TURBT Versus Surveillance Following TURBT for Intermediate-Risk NMIBC RFS Rate ▪ ▪ ▪ o o o ▪ o o ▪ ▪ o o o ▪

  27. Slide 27: CG Oncology Highlights

    CG Oncology Highlights 1 2 3 4 5

  28. Slide 28: CG Oncology Inc. Contact

    CG Oncology Inc. [email protected] 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618 [email protected] | 28

CG Oncology — Investor Presentation (June 2024) on 6ix